Immune response and tolerability of varicella vaccine in children and adolescents with systemic lupus erythematosus previously exposed to varicella-zoster virus

Clinical and Experimental Rheumatology

Volumn 30, Issue 5, 2012, Pages 791-798

  Barbosa, C M P L ^a   Terreri, M T R A ^a   Rosario P O ^a   De Moraes Pinto, M I ^a   Silva, C A A ^b   Hilario M O E ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Herpes zoster; Immunocompromised host; Systemic lupus erythematosus; Vaccine; Varicella

Indexed keywords

AZATHIOPRINE; BIKEN; CHICKENPOX VACCINE; CHLOROQUINE; CORTICOSTEROID; CYCLOSPORIN; GAMMA INTERFERON; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; UNCLASSIFIED DRUG; VIRUS ANTIGEN;

ADOLESCENT; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; CHICKENPOX; CHILD; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEVER; FLOW CYTOMETRY; FOLLOW UP; HEADACHE; HERPES ZOSTER; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; INJECTION SITE REACTION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RASH; SEROLOGY; SINGLE DRUG DOSE; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; TREATMENT RESPONSE; VACCINATION; VARICELLA ZOSTER VIRUS; VIRUS INFECTION;

ADOLESCENT; ANTIBODIES, VIRAL; BIOLOGICAL MARKERS; BRAZIL; CHICKENPOX VACCINE; CHILD; CHILD, PRESCHOOL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HERPES ZOSTER; HERPESVIRUS 3, HUMAN; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNOPHENOTYPING; INTERFERON-GAMMA; INTERFERON-GAMMA RELEASE TESTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; PROSPECTIVE STUDIES; T-LYMPHOCYTES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84870283373     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. LEE PPW, LEE T-L, HO MH-K, WONG WH, LAU YL: Herpes zoster in juvenile-onset systemic lupus erythematosus. Incidence, clinical characteristics and risk factors. Pedialr Infect Dis J 2006;8:728-32.
2. NAGASAWA K, YAMAUCHI Y, TADAY, KUSABA T, NIHO Y, YOSHIKAWA H: High incidence of herpes zoster in patients with systemic lupus erythematosus: an immunological analysis. Ann Rheum Dis 1990;49:630-3.
3. HOPE-SIMPSON RE: The nature of herpes zoster: a long term study and a new hypothesis. Proc R Soc Med 1965;58:9-20.
4. PETURSSON G, HELGASON S, GUDMUNDSSON, SIGURDSSON JA: Herpes zoster in children and adolescents. Pediatr Infect Dis J 1998;17:905-8.
5. KANG T-Y, LEE H-S, KIM T-H, JUN JB, YOO DH: Clinical and genetic risk factors of herpes zoster in patients with systemic lupus erythematosus. Rheumatol Int 2005;25:97-102.
6. LEVIN M, MURRAY M, ROTBART H, ZERBE GO, WHITE CJ, HAYWARD AR: Immune response of elderly individuals to a live attenuated varicella vaccine. J Infect Dis 1992;166:253-9.
7. OXMAN MN, LEVIN MJ, JOHNSON GR et al.: A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005;352:2271-84.
8. LEVIN MJ, OXMAN MN, ZHANG JH et al.: Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis 2008;197:825-35.
9. WEINBERG A, WIZNIA AA, LAFLEUR BJ, SHAH S, LEVIN MJ: Varicella-zoster virus-specific cell-mediated immunity in HIV-infected children receiving highly active antiretroviral therapy. J Infect Dis 2004;190:267-70.
10. GERSHON A, LEVIN MJ, WEINBERG A et al.: A phase I-II study of live attenuated varicella-zoster virus vaccine to boost immunity in human immunodeficiency virus infected children with previous varicella. Ped Inf Dis.7 2009;28:653-5.
11. RAHIER J-F, MOUTSCHEN M, VAN GOMPEL A et al.: Vaccinations in patients with immunemediated inflammatory diseases. Rheumatology (Oxford). 2010;49:1815-27.
12. HOCHBERG MC: Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
13. O'NEILL SG, ISENBERG DA: Immunizing patients with systemic lupus erythematosus: a review of effectiveness and safety. Lupus 2006;15:778-83.
14. CONTI F, REZAI S, VALESINI G: Vaccination and autoimmune rheumatic diseases. Autoimmun Rev 2008;8:124-8.
15. MILLET A, DECAUX O, PERLAT A, GROSBOIS B, JEGO P: Systemic lupus erythematosus and vaccination. Eur J Intern Med 2009;20:236-41.
16. SILVA CAA, TERRERI MTRA, BARBOSA CMPL et al.: Immunization consensus for children and adolescents with rheumatic diseases. Bras J Rheumatol 2009;49:562-89.
17. th ed. Elk Grove Village, IL: American Academy of Pediatrics: 68-104.
18. BOMBARDIER C, GLADMAN DD, UROWITZ MB, CARON D, CHANG CH: Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992;35:630-40.
19. WEISS JE, SISON CP, ILOWITE NT, GOTTIIEB BS, EBERHARD BA: Flares in pediatric systemic lupus erythematosus. J Rheumatol 2007;34:1341-4.
20. ONO E, LAFER MM, WECKX LY, GRANATO C, MORAES-PINTO M: A simple and cheaper in house varicella zoster vírus antibody indirect ELISA. Rev Inst de Med Trop Sao Paulo 2004;46:165-8.
21. DE ORY F, ECHEVARRÍA JM, KAFATOS G et al:. European seroepidemiology network 2: standardisation of assays for seroepidemiology of varicella zoster virus. J Clin Virol 2006;36:111-8.
22. CLEMENS SAC, AZEVEDO T, FONSECA JC, SILVA AC, SILVEIRA TR, CLEMENS R: Seroepidemiology of varicella in Brazil - results of a prospective, cross-sectional study. J Pediatr (Rio J) 1999;75:433-41.
23. MILLER AE: Selective decline in cellular immune response to varicella-zoster in the elderly. Neurology 1980;30:582-7.
24. LEVIN M, HAYWARD A: Prevention of herpes zoster. In: ELLIS P, WHITE C (Eds.) Varicella vaccine. Philadelphia: WB Saunders, 1996:657-76.
25. LEVIN MJ, SMITH JG, KAUFHOLD RM: Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine. J Infect Dis 2003;188:1336-44.
26. GERSHON A, MERVISH N, La RUSSA P, STEINBERG S, LO SH, HODES D: Varicella-zoster virus infection in children with underlying HIV infection. J Infect Dis 1997;176:1946-50.
27. DERRYCK A, LARUSSA P, STEINBERG S, CARPASSO M, PITTI J, GERSHON AA: Varicella and zoster in children with human immunodeficiency virus infection. Ped Inf Dis J 1998;17:931-3.
28. WOOD SM, SHAH SS, STEENHOFF AP, RUTSTEIN RM: Primary varicella and herpes zoster among HIV-infected children from 1989 to 2006. Pediatrics 2008;121:el50-156.
29. TAKAHASHI M: 25 Years' Experience with the Biken Oka strain varicella vaccine. A clinical overview. Paediatr Drugs 2001;3:285-92.
30. GREEN MR, KENNEL AS, LARCHE MJ, SEIFERT MH, ISENBERG DA, SALAMON MR: Natural Killer T cells in families of patients with systemic lupus erythematosus: their possible role in regulation of IGG production. Arthritis Rheum 2007;56:303-10.
31. GREEN MRJ, KENNEL ASM, LARCHE MJ, SEIFERT MH, ISENBERG DA, SALAMON MR: Natural killer cell activity in families of patients with systemic lupus erythematosus demonstration of a killing defect in patients. Clin Exp Immunol 2005;141:165-73.
32. MYIAMOTO M, ONO E, BARBOSA CMPL et al:. Vaccine antibodies and T and B cell interaction in juvenile systemic lupus erythematosus. Lupus 2011;20:736-44.
33. BERMAS BL, PETRI M, GOLDMAN D et al:. T helper cell disfunction in systemic lupus erythematosus (SLE). Relation to the disease activity. J Clin Immunol 1994;14:169-77.
34. th ed. Elk Grove Village, IL: American Academy of Pediatrics: 380-400.
35. BERNER BR, TARY-LEHMANN M, YONKERS NL, ASKARI AD, LEHMANN PV, ANTHONY DD: Phenotypic and functional analysis of EBV-specific memory CD8 cells in SLE. Cell Immunol 2005;235:29-38.
36. TSOKOS GC, BOUMPAS DT, SMITH PL, DJEU JY, BALOW JE, ROOK AH: Deficient gammainterferon production in patients with systemic lupus erythematosus. Arthritis Rheum 1986;29:1210-5.
37. ASANUMA H, SHARP M, MAECKER HT, MAINO VC, ARVIN AM: Frequencies of memory T cells specific for varicella-zoster virus, herpes simplex virus, and cytomegalovirus by intracellular detection of cytokine expression. J infect Dis 2000;181:859-66.
38. PARK HB, KIM KC, PARK JH et al.: Association of reduced CD4 T cell responses specific to varicella zoster virus with high incidence of herpes zoster in patients with systemic lupus erythematosus. J Rheumatol 2004;31:2151-5.
39. HARPAZ R, ORTEGA-SANCHEZ IR, SEWARD JF: Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008;57:1-30.
40. VAN ASSEN S, AGMON-LEVIN N, ELKAYAM O et al.: EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2011;70:414-22.